Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD.